Click HERE for Facit Translation

 

How Questionnaires Work

Three different forms of measures are listed: a) full scales; b) stand-alone subscales; and c) symptom indices. As a general rule the full scales (aside from select non-cancer scales) are comprised of the FACT-G (the general version of the cancer-specific QOL measure) plus an additional subscale of disease-, treatment-, or condition-specific concerns. Each scale has a unique name and acronym corresponding to the targeted issue (e.g., FACT-B for breast cancer; FACT-BMT for bone marrow transplantation; FACT-An for anemia/fatigue). Stand-alone subscales are those subscales that have demonstrated reliability and validity as independent measures, so can be administered in conjunction with the FACT-G or as a separate scale (e.g., The FACIT Fatigue Scale). Symptom indices are currently available for select tumor sites. They were derived from existing FACT disease-specific scales due to a growing need for brief symptom-based patient-reported outcome measures. The indices are comprised of symptoms considered by cancer experts to be priority symptoms for targeted tumor sites.

                 


Terminology: All questionnaires on this site are part of the FACIT measurement system. However, questionnaire names and acronyms vary. Some scales are labeled “FACIT," some “FACT," and others according to a condition or concern. The term “FACIT” was adopted in 1997, several years after the FACT Measurement System was already in place, to reflect the expansion of the original cancer questionnaire into other chronic illnesses.   


Version: FACIT questionnaires are currently available in Version 4 (since 1997).  


Categorization: The list of available FACIT scales is organized according to five categories: a) General-measures (the core measure, the non-life-threatening conditions measure, and the general population measure); b) Cancer-specific measures (breast; bladder; brain; colon; central nervous system; cervical; esophageal; endometrial; gastric; head & neck; hepatobiliary; leukemia; lung; lymphoma; melanoma; ovarian; prostate; vulvar); c) Symptom index measures (bladder; brain; breast; colorectal; head & neck; hepatobiliary; kidney; lung; ovarian; prostate) d); Treatment-specific measures (bone marrow transplantation; biologic response modifiers; neurotoxicity; taxane toxicity); e) Symptom-specific measures (anorexia/cachexia; diarrhea; anemia/fatigue; endocrine; lymphedema; neutropenia; thrombocytopenia; fecal incontinence; urinary incontinence); and f) Non-cancer-specific measures (spiritual well-being; HIV infection; multiple sclerosis; satisfaction with pharmacist; treatment satisfaction – patient and general).